Recent Updates
Recently added Catalysts
NUS

NU SKIN ENTERPRISES REPORTS RECORD FIRST-QUARTER 2021 RESULTS Company announces first-quarter revenue growth of 31% and EPS growth of 153%, raises annual guidance

Key Takeaway: NU SKIN ENTERPRISES REPORTS RECORD FIRST-QUARTER 2021 RESULTS Company announces first-quarter revenue growth of 31% and EPS growth of 153%, raises annual guidance PROVO, Utah - May 5, 2021 - Nu Skin Enterprises, Inc. (NYSE: NUS) today announced record first-quarter 2021 revenu

Full Press Release Details

NU SKIN ENTERPRISES REPORTS RECORD FIRST-QUARTER 2021 RESULTS
Company announces first-quarter revenue growth of 31% and EPS growth of 153%,
raises annual guidance
PROVO, Utah - May 5, 2021 - Nu Skin Enterprises, Inc. (NYSE: NUS) today announced record first-quarter 2021 revenue and earnings per share.
Q1 2021 vs. Prior-year Quarter
Revenue: $677.0 million; +31% +6% fx impact or $29.6 million
Earnings Per Share (EPS): $0.91; +153%
Sales Leaders: 60,619; +22%
Customers: 1,517,260; +34%
"We are very pleased with a strong start to 2021 with our highest-ever first quarter revenue and earnings per share," said Ritch Wood, chief executive officer. "Our
innovative beauty and wellness product initiatives powered by our social commerce business model led to 34 percent growth in our customer base over the prior year and a 22 percent increase in global sales leaders. We were recognized again by
Euromonitor as the world's number one beauty device systems brand.* We continue to improve our geographic balance, driven by ongoing strong performance in the West, providing a more diversified and sustainable growth profile. Our
manufacturing segment also achieved record results with 69 percent year-over-year revenue growth."
Ryan Napierski, president and CEO-elect, added, "We continue to make progress toward our vision of becoming the world's leading beauty and wellness company powered by
our dynamic affiliate opportunity platform. We added innovative products to our portfolio with the launch of ageLOC Boost and Nutricentials Bioadaptives, and our markets are forecasting strong demand for new product innovations being introduced
in the back half of the year. These include Beauty Focus Collagen+, which is the first product in a new beauty-from-within line, and ageLOC Meta, a metabolic health supplement and our next major Pharmanex product introduction. The West markets
continue to lead out in adopting our social commerce business model with triple-digit growth. Our affiliates are leveraging this model to connect with more consumers and attract people interested in building their own socially enabled affiliate
marketing business. In the East, we grew 14 percent in Japan and modestly in Mainland China and anticipate increased adoption of our social commerce strategy and digital tools."
Q1 2021 Year-over-year Operating Results
Revenue: $677.0 million compared to $518.0 million +6% fx impact
Gross Margin: 74.8% compared to 75.7% Nu Skin business was 77.8% compared to 78.1% Impacted by growth in manufacturing segment
Selling Expenses: 40.4% compared to 39.8% Nu Skin business was 43.4% compared to 42.0%
G&A Expenses: 25.1% compared to 28.9%
Operating Margin: 9.3% compared to 7.1%
Other Income / (Expense): $1.6 million compared to ($6.2) million
Income Tax Rate: 26.5% compared to 35.1% Benefited by geographic mix
EPS: $0.91 compared to $0.36
Dividend Payments: $19.3 million
Stock Repurchases: $50.4 million $275.4 million remaining in authorization
Q2 and Full-year 2021 Outlook
Q2 2021 Revenue: $680 to $705 million; +11 to 15% Approximately +5% fx impact
Q2 2021 EPS: $0.97 to $1.07; +20 to 32%
2021 Revenue: $2.80 to $2.87 billion; +9 to 11% Approximately +3 to 4% fx impact
2021 EPS: $ 4.05 to $4.30; +12 to 18%
Mark Lawrence, chief financial officer, added, "During the quarter, we continued our focus on generating shareholder
value by improving operating margin through G&A optimization and leveraging our balance sheet to repurchase nearly one million shares. We continue to create synergistic value from our Rhyz manufacturing companies as they enabled the
accelerated growth throughout the West. Given the strong start to the year, as well as the positive trends we have seen in customer and sales leader growth, we are increasing our annual revenue and EPS guidance."
About Nu Skin Enterprises, Inc.
Founded more than 35 years ago, Nu Skin Enterprises, Inc. (NSE) empowers innovative companies with sustainable solutions, opportunities, technologies and life-improving
values. The company currently focuses its efforts around innovative consumer products, product manufacturing and controlled environment agriculture technology. The NSE family of companies includes Nu Skin, which develops and distributes a
comprehensive line of premium-quality beauty and wellness solutions through a global network of sales leaders in Asia, the Americas, Europe, Africa and the Pacific; and Rhyz, our strategic investment arm that includes a collection of sustainable
manufacturing and technology innovation companies. Nu Skin Enterprises is traded on the New York Stock Exchange under the symbol "NUS." More information is available at nuskinenterprises.com.
* Source Euromonitor International Limited; Retail Value RSP terms; all channels; 2017 to 2020. Beauty Systems are at-home Skin Care
Beauty Devices that are exclusively paired or recommended to be used with a topical consumable of the same brand. Claim verification based on Euromonitor custom research and methodology conducted January-March of 2021. Sales of at-home skin care
beauty devices includes sales of electric facial cleansers as defined in Passport database. This category does not include hair care/removal appliances, body shavers, and oral care appliances.
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended,
that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to,
statements of management's expectations regarding the company's performance, growth, product pipeline and product introductions, customers and sales leaders, affiliates, strategies and initiatives; projections regarding revenue, earnings per
share, foreign currency fluctuations and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe,"
"expect," "anticipate," "project," "outlook," "guidance," "plan," "forecast," "expand," "will," "would," "could," "may," "might," the negative of these words and other similar words.
The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ
materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:
The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated
risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided, and the company assumes no
duty to update the forward-looking statements contained in this release to reflect any change except as required by law.
Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company's performance. It
is calculated by translating the current period's revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period's revenue. The company believes that
constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company's revenue from period to period.
The Company's revenue results by segment for the three-month periods ended March 31 are presented in the following table (in thousands).
Three Months Ended March 31, Constant- Currency
2021 2020 Change Change
Nu Skin
Mainland China $ 149,593 $ 137,696 9 % 1 %
Americas/Pacific 149,465 74,573 100 % 97 %
South Korea 81,131 75,719 7 % -
EMEA 76,180 35,403 115 % 98 %
Japan 69,864 61,300 14 % 11 %
Southeast Asia 67,585 69,586 (3 )% (5 )%
Hong Kong/Taiwan 36,345 35,827 1 % (3 )%
Other 705 773 (9 )% (9 )%
Total Nu Skin 630,868 490,877 29 % 22 %
Manufacturing 45,985 27,147 69 % 69 %
Grow Tech 173 4 4,225 % 4,225 %
Total $ 677,026 $ 518,028 31 % 25 %
The company's Customers and Sales Leaders statistics by segment as of March 31, 2021 and 2020 are presented in the following table:
As of March 31, 2021 As of March 31, 2020 % Increase (Decrease)
Customers Sales Leaders Customers Sales Leaders Customers Sales Leaders
Mainland China 316,000 16,716 271,536 16,159 16 % 3 %
Americas/Pacific 407,413 12,340 214,139 6,930 90 % 78 %
South Korea 152,390 7,099 174,004 6,608 (12 )% 7 %
EMEA 296,001 7,950 140,344 4,237 111 % 88 %
Japan 126,525 6,131 119,784 5,635 6 % 9 %
Southeast Asia 152,889 6,882 145,116 6,634 5 % 4 %
Hong Kong/Taiwan 66,042 3,501 66,024 3,348 - 5 %
Total 1,517,260 60,619 1,130,947 49,551 34 % 22 %
"Customers" are persons who
purchased products directly from the company during the previous three months. Our Customer numbers do not include consumers who purchase products directly from members of our sales force.
independent distributors, and sales employees and independent marketers in China, who achieve certain qualification requirements.
NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)
Three Months Ended March 31,
2021 2020
Revenue $ 677,026 $ 518,028
Cost of sales 170,566 125,793
Gross profit 506,460 392,235
Operating expenses:
Selling expenses 273,746 206,042
General and administrative expenses 169,801 149,628
Total operating expenses 443,547 355,670
Operating income 62,913 36,565
Other income (expense), net 1,582 (6,174 )
Income before provision for income taxes 64,495 30,391
Provision for income taxes 17,065 10,661
Net income $ 47,430 $ 19,730
Net income per share:
Basic $ 0.94 $ 0.36
Diluted $ 0.91 $ 0.36
Weighted-average common shares outstanding (000s):
Basic 50,706 55,059
Diluted 52,172 55,101
March 31, 2021 December 31, 2020
ASSETS
Current assets:
Cash and cash equivalents $ 339,099 $ 402,683
Current investments 23,615 21,216
Accounts receivable, net 60,625 63,370
Inventories, net 363,431 314,366
Prepaid expenses and other 114,118 101,563
Total current assets 900,888 903,198
Property and equipment, net 464,247 468,181
Operating lease right-of-use assets 147,129 155,104
Goodwill 202,979 202,979
Other intangible assets, net 87,135 89,532
Other assets 147,721 138,082
Total assets $ 1,950,099 $ 1,957,076
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 67,083 $ 66,174
Accrued expenses 404,493 446,682
Current portion of long-term debt 90,000 30,000
Total current liabilities 561,576 542,856
Operating lease liabilities 108,237 112,275
Long-term debt 298,120 305,393
Other liabilities 110,692 102,281
Total liabilities 1,078,625 1,062,805
Commitments and contingencies
Stockholders' equity:
Class A common stock - 500 million shares authorized, $0.001 par value, 90.6 million shares issued 91 91
Additional paid-in capital 579,204 579,801
Treasury stock, at cost - 40.4 million and 39.7 million shares (1,505,076 ) (1,461,593 )
Accumulated other comprehensive loss (71,626 ) (64,768 )
Retained earnings 1,868,881 1,840,740
Total stockholders' equity 871,474 894,271
Total liabilities and stockholders' equity $ 1,950,099 $ 1,957,076
Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com, (801) 345-3577
Last updated: May 5, 2021